The state of Arizona currently has 4 active clinical trials seeking participants for Narcolepsy research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa.
Ph4 PSG Combined JZP258-407
Recruiting
This study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic hypersomnia (IH) or narcolepsy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2024
Locations: Perseverance Research Center, LLC, Scottsdale, Arizona
Conditions: Idiopathic Hypersomnia, Narcolepsy
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
Recruiting
The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/10/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Narcolepsy
Child and Adolescent Registry for Participants With Narcolepsy
Recruiting
CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed. The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the United States. For more information about the study or to access the Online Patient Enrollment System, visit the CATNAP website: https://catnap.healthie.net/welcome or email catnap@pulseinfoframe.com.... Read More
Gender:
All
Ages:
17 years and below
Trial Updated:
03/28/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona +1 locations
Conditions: Narcolepsy
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
Recruiting
This study is a multi-center, double-blind, placebo-controlled, randomized Phase 3 trial to assess the safety and efficacy of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).
Gender:
All
Ages:
Between 15 years and 75 years
Trial Updated:
03/03/2023
Locations: Clinical Research Site, Peoria, Arizona +1 locations
Conditions: Narcolepsy, Cataplexy, Excessive Daytime Sleepiness